African Americans are twice as likely to suffer from multiple myeloma and the mortality is twice as high as that of Caucasian Americans.
1 Although multiple myeloma seems to be more aggressive in African Americans, little is known regarding outcomes of high-dose chemotherapy and autologous stem cell transplantation in this population. A recent retrospective analysis comparing outcomes after high-dose chemotherapy and autologous stem cell transplantation in 38 African American patients with multiple myeloma to 32 non-African American patients found no difference in overall survival between the two groups and improved progression-free survival in African Americans. 2 We have conducted a similar retrospective review of 86 consecutive patients (32 African Americans and 54 nonAfrican Americans) who underwent high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma between July 1991 and November 2004 at our institution and also found no difference in overall survival but a shorter progression-free survival.
The records of 86 patients with multiple myeloma who received consecutive autologous stem cell transplantation at Henry Ford Hospital were reviewed. Patients included 32 African Americans and 54 non-African Americans. Institutional Review Board approval was obtained before chart review. The conditioning regimen for stem cell transplantation was melphalan 200 mg/m 2 in 57 patients and melphalan 140 mg/m 2 plus TBI 1200 cGy in 29 patients. Cytogenetic studies were available for 72% of African Americans and 54% of non-African Americans (Table 1) .
Differences between the two groups were calculated by the Student's t-test and w 2 test. Survival curves were drawn using the Kaplan-Meier method and comparisons were performed by the log-rank test. Potential confounding factors considered in this analysis were age (o60 or X60), gender, race (African Americans or non-African Americans), conditioning regimens and cytogenetic abnormalities (chromosome13 deletion). To evaluate the influence of these factors on progression-free survival, Cox proportional hazard model was used. Factors associated with a borderline significance (Po0.10) in univariate analysis were subjected to multivariate analysis using backward stepwise proportional-hazard model. Values of Po0.05 were considered statistically significant.
There were no significant differences observed between African Americans and non-African Americans in regards to gender, conditioning regimens, multiple myeloma subtype, cytogenetic abnormalities and disease status at the time of transplant. There was also no significant difference in overall survival between African Americans and non-African Americans with a median follow-up of 2.7 years (Figure 1b) . There was no difference in the complete remission rate between the two groups following autologous stem cell transplantation; 9/32 (28%) in African Americans and 16/54 (30%) in non-African Americans. Contrary to the results published by Saraf et al.,
2 the progression-free survival in African Americans was significantly shorter than in non African Americans (Figure 1a , P ¼ 0.025). Our results show that African Americans have a shorter progression-free survival than non-African Americans. This effect was independent of cytogenetics, conditioning regimens, gender, multiple myeloma subtype, disease status at time of transplant or age. The risk of relapse after autologous stem cell transplantation in African Americans was more than double the risk of relapse in non-African Americans (hazard ratio of 2.55).
These results are in contrast to those recently published by Saraf et al., 2 in which African Americans had significantly longer progression-free survival than nonAfrican Americans. Both studies demonstrate equivalent overall survival between the groups and approximate the expected overall survival in non-African Americans after autologous transplantation. 3 The reason for the difference in progression-free survival between the two studies is unclear and likely to be related to the small sample size in both studies. It is also difficult to attribute firmly any difference in progression-free survival to race alone when cytogenetic studies are not available in all the patients.
Larger, prospective studies are needed to determine whether outcomes for African Americans with multiple myeloma after autologous stem cell transplantation differ from those of non-African Americans. Furthermore, other variables that may impact transplant outcome such as socioeconomic status and accessibility to medical care should be considered. 4 At present, we may conclude that African Americans with multiple myeloma appear to have similar overall survival to non-African Americans after autologous transplantation. curves in African American (AA) and non-African American (non-AA) multiple myeloma patients after autologous stem cell transplantation.
